MedTrace Logo

A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis

NCT04791319 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 199

Last updated 2023-03-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of bermekimab in participants with moderate to severe atopic dermatitis (AD).

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

Placebo

Placebo will be administered subcutaneously.

DRUG

Bermekimab

Bermekimab will be administered subcutaneously.

DRUG

Dupilumab

Dupilumab will be administered subcutaneously.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-03
Primary Completion
2022-02-02
Completion
2022-03-31
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Germany
  • Japan
  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04791319 on ClinicalTrials.gov